|
Dr. Navre brings twenty years of experience in applying innovative technologies to drug discovery, with a strong focus on proteases. He received his Ph.D. in Biochemistry from the University of California at Berkeley and undertook post-doctoral training at Stanford University as a Damon Runyon fellow. In 1991 Dr. Navre joined Affymax, where he built the Enzymology group, and developed an innovative system for mapping protease specificity using polyvalent phage display, the use of which has been published on for a variety of therapeutically relevant proteases. Following Affymax’s acquisition by Glaxo-Wellcome, Dr. Navre worked extensively with international teams including Glaxo’s Protease Systems-Based Research group, the Antibacterial Exploratory Discovery Board, as well as the Global Scientific Computing Board. Prior to joining Catalyst, Dr. Navre was Vice President of Biology at Takeda San Diego (formerly Syrrx), where he participated in numerous discovery programs, including the development of SYR322, an inhibitor of the protease DPP IV, which is now in Phase III clinical testing for Type II diabetes. | 